Research map: Cancer Therapy-Related Cutaneous Toxicities: Prognostic Biomarkers, Immunologic Endotypes, and Novel Therapeutic Strategies

Back to the article

Papers in this map

  1. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade · Mark Ayers · 2017 · 3986 citations · Cited by this paper
  2. The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands · 2026 · Related
  3. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies · Jérôme Galon · 2019 · 3583 citations · Cited by this paper
  4. Hub Gene Clusters Reveal Dysregulated Synaptic Neurotransmitter Signaling Pathways and Drug Repurposing Prospect in Brain Tumors · 2026 · Related
  5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  6. Navigating Rarity: Pathological Challenges and Diagnostic Ambiguity in Rare Gliomas—A Case Series with a Focus on Personalized Treatment and Quality of Life · 2025 · Related
  7. Guidelines of care for the management of primary cutaneous melanoma · Susan M. Swetter · 2018 · 737 citations · Cited by this paper
  8. Molecular Insight and Antioxidative Therapeutic Potentials of Plant-Derived Compounds in Breast Cancer Treatment · 2025 · Related
  9. Cold and hot tumors: from molecular mechanisms to targeted therapy · Bo Wu · 2024 · 669 citations · Cited by this paper
  10. Advancing Immunotherapy in Cervical Cancer: Biological Rationale, Clinical Evidence, and Biomarker Standardization · 2026 · Related
  11. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab · Camille Hua · 2015 · 659 citations · Cited by this paper
  12. Cutaneous adverse events associated with new cancer therapies · 2026 · Related
  13. Cutaneous side-effects of kinase inhibitors and blocking antibodies · Caroline Robert · 2005 · 555 citations · Cited by this paper
  14. Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data · 2026 · Related
  15. Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining? · Román Pérez-Soler · 2005 · 491 citations · Cited by this paper
  16. STEPP for the EGFR Inhibitor–Induced Rash—Definitely a Step in the Right Direction · 2010 · Related
  17. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer · Mario E. Lacouture · 2010 · 485 citations · Cited by this paper
  18. Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors. · Related
  19. Immune checkpoint inhibitor–related dermatologic adverse events · Amaris N. Geisler · 2020 · 482 citations · Cited by this paper
  20. Preventive and Therapeutic Interventions for Anticancer Drug-induced Dermatologic Toxicities: a Scoping Review · 2026 · Related
  21. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology · John A. Thompson · 2022 · 431 citations · Cited by this paper
  22. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors · Anna Liza C. Agero · 2006 · 383 citations · Cited by this paper
  23. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails · Mario E. Lacouture · 2018 · 364 citations · Cited by this paper
  24. Immunologic tumor microenvironment modulators for turning cold tumors hot · Gholamreza Reza Khosravi · 2024 · 362 citations · Cited by this paper
  25. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches · Muhammad Tufail · 2025 · 347 citations · Cited by this paper
  26. Current understanding and management of CAR T cell-associated toxicities · Jennifer N. Brudno · 2024 · 292 citations · Cited by this paper
  27. Treatment Outcomes of Immune-Related Cutaneous Adverse Events · Gregory S. Phillips · 2019 · 239 citations · Cited by this paper
  28. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma · Jaroslav Žák · 2024 · 191 citations · Cited by this paper
  29. Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide · Florian Scotté · 2018 · 172 citations · Cited by this paper
  30. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024 · Susan M. Swetter · 2024 · 158 citations · Cited by this paper
  31. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin · Mario E. Lacouture · 2022 · 156 citations · Cited by this paper
  32. MicroRNA-146a suppresses IL-17–mediated skin inflammation and is genetically associated with psoriasis · Ankit Srivastava · 2016 · 141 citations · Cited by this paper
  33. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion · Karin Potthoff · 2010 · 132 citations · Cited by this paper
  34. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials · Rik Jasper Verheijden · 2024 · 115 citations · Cited by this paper
  35. Turning cold into hot: emerging strategies to fire up the tumor microenvironment · Kejing Ma · 2024 · 113 citations · Cited by this paper
  36. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review · Peng Cao · 2022 · 98 citations · Cited by this paper
  37. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways · Arefeh Zabeti Touchaei · 2024 · 97 citations · Cited by this paper
  38. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors · Ralf‐Dieter Hofheinz · 2016 · 92 citations · Cited by this paper
  39. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024 · Claus Garbe · 2024 · 92 citations · Cited by this paper

Source: OpenAlex (CC0)